荷兰罕见出血性疾病患者的治疗:RBiN研究的真实世界数据
RBiN研究纳入荷兰全部六家血友病治疗中心的263例罕见凝血因子缺乏或纤维蛋白溶解性疾病患者,从病历提取一般治疗计划,并访谈有牙科或手术操作史的患者。结果显示84%有记录的一般治疗计划,同一疾病患者间治疗计划异质,未接受围操作期止血治疗时牙科操作出血50%、手术操作出血53%,接受止血治疗时分别为28%和19%。
要点
- 84%的罕见出血性疾病患者有记录的一般治疗计划,同一疾病患者间治疗计划存在异质性。
- 未接受围操作期止血治疗时,牙科操作出血率为50%,手术操作出血率为53%。
- 接受围操作期止血治疗时,牙科操作出血率为28%,手术操作出血率为19%。
核心结论
- 罕见出血性疾病患者的一般治疗计划存在较大异质性。
- 侵入性操作后出血常见,无论诊断前后,与因子活性水平无关,尤其当围操作期治疗被省略时。
- 改进的指南应包含针对每种罕见出血性疾病的统一止血产品推荐,并强调个体出血史的相关性。
研究设计与样本
- RBiN研究纳入来自荷兰全部六家血友病治疗中心的罕见出血性疾病患者。
- 从患者病历中提取一般治疗计划。
- 对有牙科或手术操作史的患者进行访谈,了解围操作期治疗使用及出血并发症情况。
主要发现
- 共纳入263例罕见凝血因子缺乏或纤维蛋白溶解性疾病患者。
- 84%的患者有记录的一般治疗计划。
- 同一罕见出血性疾病患者的一般治疗计划存在异质性,尤其在因子XI缺乏症中。
- 共报告308例牙科操作和408例手术操作。
- 未接受止血治疗时,牙科操作出血率为50%,手术操作出血率为53%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with rare inherited bleeding disorders (RBDs) exhibit hemorrhagic symptoms, varying in type and severity, often requiring only on-demand treatment. Prolonged bleeding after invasive procedures is common. Adequate peri-procedural therapy may reduce this bleeding risk. OBJECTIVE: To describe general treatment plans of RBD patients and evaluate the use of peri-procedural hemostatic therapy. METHODS: In the Rare Bleeding Disorders in the Netherlands (RBiN) study, RBD patients from all six Dutch Hemophilia Treatment Centers were included. General treatment plans were extracted from patient files. Patients with a dental or surgical procedure in their history were interviewed about use of peri-procedural treatment and bleeding complications. RESULTS: Two-hundred sixty-three patients with a rare coagulation factor deficiency or fibrinolytic disorder were included. Eighty-four percent had a documented general treatment plan. General treatment plans of patients with the same RBD were heterogeneous, particularly in factor XI deficiency. Overall, 308 dental and 408 surgical procedures were reported. Bleeding occurred in 50% of dental and 53% of surgical procedures performed without hemostatic treatment and in 28% of dental and 19% of surgical procedures performed with hemostatic treatment. Not only patients with severe RBDs, but also patients with mild deficiencies, experienced increased bleeding without proper hemostatic treatment. CONCLUSION: Large heterogeneity in general treatment plans of RBD patients was found. Bleeding after invasive procedures was reported frequently, both before and after RBD diagnosis, irrespective of factor activity levels and particularly when peri-procedural treatment was omitted. Improved guidelines should include uniform recommendations for most appropriate hemostatic products per RBD and emphasize the relevance of individual bleeding history.
引用
- Maas DPMSM, Saes JL, Blijlevens NMA, et al. Treatment of patients with rare bleeding disorders in the Netherlands: Real-life data from the RBiN study. J Thromb Haemost. 2022. PMID: 35038781. doi:10.1111/jth.15652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。